The utility of the pfxa3 probe for direct molecular diagnosis of the fragile X (FRAXA) 
Abstract
The utility of the pfxa3 probe for direct molecular diagnosis of the fragile X (FRAXA) has been established. This probe detects amplification of an unstable DNA element consisting of variable length CCG repeats. The size of the amplified fragment is correlated with phenotype and was determined using Pstd digested DNA in family members. In 35 families with the fragile X, there was correspondence in 183 cases between the presence of an amplified unstable element and the presence of the fragile X chromosome independently determined by cytogenetics, position in the pedigree, or linked DNA markers flanking the fragile X. There was also correspondence in 124 cases between the presence of the normal 1 0 kb Psd fragment and absence of the fragile X chromosome independently determined by linked flanking markers. Six additional families considered to be isolated cases of 'fragile X' had been diagnosed before recognition of FRAXD. The pfxa3 probe confirmed the cytogenetic diagnosis in three families, the other three being rediagnosed as non-fragile X. A further two Fragile X syndrome is the most common familial type of mental retardation in humans. The syndrome is associated with the folate sensitive fragile site at Xq27.3 (FRAXA). Families with fragile X syndrome had been previously ascertained on the basis of cytogenetic demonstration of the fragile site in a mentally impaired family member.
Genetic counselling for family members has been complicated by three factors. These are incomplete penetrance of cytogenetic expression of the fragile site in a proportion of female carriers, the occurrence of transmitting males who have the fragile X genotype but do not show mental impairment, and the presence of a common fragile site, FRAXD, ar Xq27.21 which can be expressed at low frequency under the same conditions used to detect the fragile X. Transmitting males (defined as unaffected carrier males who have reproduced or have the potential to reproduce) have been detected either by risk analysis using closely linked polymorphic markers flanking the fragile X2 or by their position in the pedigree. The occurrence of these asymptomatic male carriers is a unique phenomenon among X linked genetic disorders. However, the most puzzling phenomenon associated with fragile X has been the Sherman paradox,34 suggesting a progressive increase in severity from generation to generation.
Molecular characterisation of the fragile X in three laboratories-7 has made possible a direct test for the fragile X genotype in affected families. give the necessary resolution on Southern analysis to distinguish male transmitters from pS8 normal males, to separate male transmitters from affected males, and to differentiate normal females from carrier females9 (fig 1) . Diagnosis is unambiguous in males. Hybridisation with PstI digested chromosomal DNA gives a 1-0 kb band in normal non-transmitting males, 1)(, a band of up to 1-6 kb in male transmitters of (5) the fragile X, and one or more bands of greater than 1-6 kb in males with fragile X syndrome. 17 and IV.18) ascertained as probable carriers (99%) using linked markers were shown as definite carriers using pfxa3. The remaining family members at low risk using linked markers (III.1, III.5, IV.3, IV.6, IV.9, IV.11, IV.13, IV.14, IV.15, IV.16, IV.20, IV.21) were confirmed as non-carriers using the pfxa3 probe. (fig 2) . Occasionally there was a small decrease in the size of the unstable fragments when transmitted from one generation to the next. In fig 1, for example, the carrier mother in lane 1 has a 1-3 kb fragment which reduces to 1-2 kb in her male transmitter son, shown in lane 2. In one unresolved case a normal pfxa3 fragment in double dose was detected from a female with no abnormal fragment, who had a carrier haplotype determined by the AC repeat markers DXS297, DXS548 (150 kb proximal to FRAXA), and FRAXAC2 (within 10kb and distal to FRAXA). This apparent contradiction might arise from a sample error causing misinterpretation of linkage data or from contraction of an amplified fragment during transmission from mother to daughter.
All subsequent referrals (222 cases from confirmed fragile X families), in which carrier status had not been predetermined by linked markers, were assessed using the pfxa3 and pS8 probes hybridised to PstI digested DNA (table B) . Frequently, subjects from fragile X families had heard of recent progress in the diagnosis of the fragile X and requested testing when their pregnancy had been confirmed (in the case of females) and when pregnancy for their daughters had been confirmed (in the case of potential male transmitters). The 135 female genotype results determined by direct diagnosis alone agreed with dosage analysis. In one case of male transmission a significant decrease in the size of the unstable element was observed. A mildly affected male with a smear of PstI bands (1 -8 kb to 2-1 kb) had reproduced and passed on a fragment of 1-3 kb to one daughter and 1-2 kb to his other daughter. In the normal females in tracks 3 and 7 the intensity of the 1x0 kb fragment of pfxa3 is clearly greater than that of pS8 owing to the presence of two doses of DNA from two normal X chromosomes. While relative intensity of the pfxa3 fragment compared with the pS8 fragment may vary from one hybridisation to the next, depending on variations in concentration and labelling efficiency of each of the probes, the ratio of the 1-0 kb pfxa3 fragment to the 0-8 kb pS8 fragment within lanes for any one hybridisation remains constant such that it is possible to verify the primary diagnosis of carrier status. This dosage analysis is independent of the amount of DNA in different lanes, the relationship between the 1-0 pfxa3 fragment and pS8 is constant for comparison between normal males and normal females (fig 1, tracks 3, 7, and 8) , and the procedure was found to be reliable if the intensity of the 10 kb pfxa3 and 0-8kb pS8 hybridising fragments were approximately equivalent. Assessment of dosage agreed with observed presence or absence of the pfxa3 fragment for the 135 females tested (table B) . Dosage analysis cannot be applied to the amplified pfxa3 fragment because of the propen- 
FAMILIES WITH ISOLATED CASES OF FRAGILE X SYNDROME
In addition to the familial cases described above, there were families with isolated cases which were confirmed as fragile X by detection of the unstable amplified fragment using pfxa3. Two of these families are shown in fig 3 . Fig 3A shows (2) carrier female, (3) normal n normal male, (5) carrier female, (6) normal male, (7) (fig 1) . families PCR based diagnosis by linked AC repeat amplified markers would provide rapid exclusion; howascertain-ever, a positive PCR diagnosis by linkage distal to would need the additional pfxa3 result. Carrier ng probes males would be predicted to be mentally unaf-:istence of fected transmitters if the PstI fragment size ve fragile was 1-6 kb or less and mentally affected if it close to exceeded 1-6 kb. Carrier females would be related to predicted to be mentally unaffected if the PstI FRAXA) fragment size was 1 6 kb or less. However, FRAXD) unlike males, there are at present insufficient data to enable phenotypic prediction for a female fetus who has a specific PstI fragment size which is greater than 1 6 kb. Having eliminated the possibility of mental impairment for gment in carrier females with PstI fragment sizes of 1 6 kb nendelian or less, the remaining carrier females with PstI related to fragment sizes exceeding 1 6 kb must as a group licated by be at greater risk of mental impairment than the ability in risks given for the unsubdivided group.4 These -neration, risks were 32% when the fragile X was passed one man through an unimpaired mother and 55% when It was passed through an impaired mother. by check-) analyse A source Conclusions i plasmid The pfxa3 probe is a reliable diagnostic tool minating for detecting fragile X genotype and predicting ing from fragile X phenotype when applied to PstI stion in a digested DNA. Used in conjunction with the patterns pS8 probe, results may be checked for consistacts need ency by dosage analysis. Alternatively, used in conjunction with closely linked and highly polymorphic AC repeat markers, results may be confirmed by family analysis without the need for laborious determination of RFLP markers by Southern analysis. There is no need for computerised risk analysis when using markers virtually in absolute linkage with FRAXA. These confirmatory procedures guard against the possibility of false positive molecular diagnosis caused by plasmid contamination or incomplete digestion. They also guard against false negative molecular diagnosis in those females who have not been cytogenetically tested and who have a low intensity smear of abnormal pfxa3 bands which could be easily masked by low level background. Such females are usually cytogenetically positive and therefore are unlikely to be misdiagnosed when parallel cytogenetic examination has been carried out. Carrier females who are cytogenetically negative are detectable without difficulty using the pfxa3 probe because they usually have only a single strongly hybridising fragment of 1-6 kb or less apart from the normal 1-0 kb fragment. Confirmatory family studies involving the AC repeat markers FRAXAC2 or DXS548 could be considered for inclusion in routine diagnostic protocols, not only to confirm the pfxa3 diagnosis and to carry out rapid PCR based prenatal diagnosis of genotype, but also to check for sample misidentification which can cause both false positive and false negative results.
The advent of molecular diagnosis raises the question of the role of cytogenetic analysis. Cytogenetic and molecular procedures will continue to be carried out in parallel until laboratories gain experience in molecular diagnosis. The initial ascertainment of fragile X families with amplification of the CCG repeat is likely to continue to be made by the cytogenetics laboratory from referrals for delayed development, or mental retardation, resulting from many causes. Molecular and cytogenetic diagnosis of fragile X syndrome might be complicated by a small number of cases which do not have an unstable element. These could result from mutation within the associated gene other than at the CCG repeat, such as a point mutation, microdeletion, or microduplication. One deletion has been detected and the extent of this deletion is being characterised in an affected boy where the pfxa3 probe failed to hybridise to PstI or EcoRI digested DNA (unpublished data).
PCR amplification of the polymorphic CCG repeat from normal chromosomes and those with small CCG amplifications now enables direct sizing of alleles at the fragile X locus.8
This analysis has established the allele distributions of this polymorphism in normal males and in male transmitters and confirmed an upper limit for amplification of 600 bp in transmitting males. Accurate delineation of these two groups by direct PCR genotyping would be preferable to separation based on estimation of PstI fragment size by Southern analysis. The PCR results, however, must be interpreted with caution given the extent of somatic instability in affected males, which may give rise to one or more additional bands in the normal to transmitter range. This inherent difficulty precludes PCR analysis of CCG amplification from prenatal diagnosis. Conversely, direct PCR genotyping will exclude carrier state in females with two normal alleles as long as each corresponds to the unaffected allele of a parent or sib. Direct PCR genotyping has not been demonstrated for the large amplifications in excess of 600 bp. It is most likely that, together with PCR based genotyping of flanking AC repeats,1' the PCR analysis of the fragile X CCG repeat will supplement, rather than replace, direct detection by Southern blots.
Note added in proof Experience with direct molecular diagnosis of fragile X has also been reported using the 
